Valeant adds recall to long list of problems

Add to Valeant Pharmaceuticals' ($VRX) growing list of problems a manufacturing mess-up that is leading to a recall of a cholesterol fighter.

According to the most recent FDA Enforcement Report, the Canadian drugmaker is recalling 3,341 bottles of fenoglide tablets after the batch failed dissolution testing at the 24-month mark. The FDA indicates the drugmaker first initiated the recall in September. The drug is used to treat high cholesterol and triglycerides.

The recall is much smaller than one about a year ago, when Valeant recalled nearly 206,000 bottles of the blood pressure medication Vaseretic because of labeling problems. At the same time, it recalled more than 35,000 tubes of hydrocortisone butyrate cream for not meeting potency standards at the 18-month mark.

The fenoglide recall is just a blip for a company under siege. Valeant has been called to account for its now-severed relationship with specialty pharmacy Philidor. Questions arose after a short seller suggested that Valeant used sales from Philidor to juice its top-line numbers. A more recent report says the company's employees were deeply involved in running the pharmacy before the drugmaker cut off the relationship last month.

Before the Philidor scandal broke, Valeant had already been called to account to federal lawmakers for jacking up the prices of some of its drugs and has also been subpoenaed by federal prosecutors seeking info on its pricing methods.

- here's the recall notice

Suggested Articles

McCallum was hit with a warning letter from the FDA for testing issues with its products and failing to keep appropriate records.

The FDA made public a voluntary recall of sterile injectables made by Coastal Meds of Mississippi, after visible particles were found in some vials.

It’s been a strange road for BMS' Opdivo-Yervoy combo in first-line kidney cancer, but the New Jersey drugmaker finally has a go-ahead.